U.S. Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology (Cytogenetic, Biochemical, Molecular Testing), By Test Type (Predictive Testing, Diagnostic Testing), By End-use (Hospitals, Clinics), And Segment Forecast

Market Size & Trends

The U.S. hereditary cancer testing market was estimated at USD 1.93 billion in 2024 and is projected to reach USD 5.76 billion by 2033, growing at a CAGR of 13.32% from 2025 to 2033. The U.S. hereditary cancer testing market is driven by growing awareness of inherited cancer risks, with 5-10% of cancers linked to germline mutations. Rising adoption of guideline-based screening from NCCN and ACOG, coupled with FDA authorization of panels, is boosting clinician confidence and payer coverage. Technological advancements such as integration of DNA/RNA sequencing, digital screening tools, and combined germline-somatic profiling are expanding clinical utility. Increasing partnerships, patient education initiatives, and insurance support are further accelerating access, positioning hereditary testing as a cornerstone of precision oncology.

In the United States, between five and ten percent of all cancers are associated with inherited mutations in cancer predisposition genes. These hereditary mutations, passed down through families, increase the risk of developing cancers such as breast, ovarian, colorectal, prostate, and others. While most of the estimated 270,000 annual breast cancer cases among women, 2,000 among men, and 20,000 ovarian cancer cases occur sporadically, a notable proportion is hereditary. This underscores the importance of genetic testing as a tool for both early detection and preventive healthcare. The National Comprehensive Cancer Network (NCCN) has established guidelines to identify individuals most likely to carry mutations, primarily based on personal and family cancer histories. Yet, despite the strength of these guidelines, hereditary testing has historically been underutilized, partly because of inconsistent interpretation across laboratories and limited patient access.

U.S. Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the hereditary cancer testing market report on the basis of test type, technology, cancer, andend-use:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Ovarian Cancer
• Prostate Cancer
• Stomach/Gastric Cancer
• Melanoma
• Sarcoma
• Uterine Cancer
• Pancreatic Cancer
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cytogenetic
• Biochemical
• Molecular Testing
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Predictive Testing
• Diagnostic Testing
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Centers
• Hospitals
• Clinics

Please note The report will be delivered in 2-3 business days upon order notification. Show more